VKTX ▲ +28.7% - Viking Therapeutics, Inc. $VKTX VKTX - Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens Viking Therapeutics shares surged 28.7% after the company announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, showing that multiple maintenance dosing regimens were effective. The dual-action drug candidate's successful demonstration of sustained efficacy across different dosing approaches validates the company's therapeutic approach and suggests a flexible path toward commercialization. 22-SEP-2026 07:06 AM ET